NCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
Clinical Trials
89 trialsNCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT03040999 2026-02-04
KEYNOTE-412
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04504942 2026-01-23
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
CytoDyn, Inc.
Phase 2 Completed
NCT03444714 2025-09-15
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
Coordination Pharmaceuticals, Inc.
Phase 1 Completed
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT03724890 2025-04-10
Study of Avelumab-M3814 Combinations
EMD Serono
Phase 1 Completed
NCT01249352 2025-03-31
NICE
Eurofarma Laboratorios S.A.
Phase 2/3 Completed
NCT03576612 2025-02-14
GMCI
Candel Therapeutics, Inc.
Phase 1 Completed
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT02383498 2024-05-20
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
NantCell, Inc.
Phase 2 Completed
NCT03165994 2024-05-02
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Apexigen America, Inc.
Phase 2 Completed
NCT03776071 2024-04-22
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma LLC
Phase 3 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT04551950 2024-03-08
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
EMD Serono
Phase 1 Completed
NCT02567799 2024-01-25
NSCLC
Humanetics Corporation
Phase 1/2 Completed
NCT00634231 2023-08-25
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Candel Therapeutics, Inc.
Phase 1 Completed
NCT02617589 2023-03-28
CheckMate 498
Bristol-Myers Squibb
Phase 3 Completed
NCT03770689 2023-03-21
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
EMD Serono
Phase 1/2 Completed
NCT02990468 2023-03-15
BMX-HN
BioMimetix JV, LLC
Phase 1/2 Completed
NCT03867123 2023-02-21
A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
Laminar Pharmaceuticals
Phase 1 Completed
NCT03335540 2022-09-26
ADVISE
Bristol-Myers Squibb
Phase 1 Completed
NCT01265849 2022-08-19
IT-MATTERS
CEL-SCI Corporation
Phase 3 Completed
NCT03438318 2022-08-03
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 1 Completed
NCT02022098 2022-06-23
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
Debiopharm International SA
Phase NA Completed
NCT00004202 2021-08-26
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT00005887 2021-08-23
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT03349710 2021-08-09
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT02903069 2021-04-19
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Celgene
Phase 1 Completed
NCT02379845 2021-04-06
NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall
Nanobiotix
Phase 2/3 Completed
NCT01017549 2020-08-13
Post Market Study Using the Xoft Axxent System
Xoft, Inc.
Phase NA Completed
NCT00402116 2020-08-06
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Eli Lilly and Company
Phase 1/2 Completed
NCT01390948 2020-08-06
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
Hoffmann-La Roche
Phase 2 Completed
NCT01790503 2020-06-30
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Daiichi Sankyo
Phase 1/2 Completed
NCT02799238 2020-04-30
ALECSAT
CytoVac A/S
Phase 2 Completed
NCT00977431 2019-02-18
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
Boehringer Ingelheim
Phase 1 Completed
NCT01860638 2018-04-30
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
Hoffmann-La Roche
Phase 2 Completed
NCT01142778 2018-03-16
AVATAXHER
Hoffmann-La Roche
Phase 2 Completed
NCT01496131 2018-03-09
Tecemotide (L-BLP25) in Prostate Cancer
EMD Serono
Phase 2 Completed
NCT01384799 2018-02-22
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Curis, Inc.
Phase 1 Completed
NCT00943826 2017-09-25
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
Phase 3 Completed
NCT02107235 2017-06-23
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Traws Pharma, Inc.
Phase 1 Completed
NCT00626639 2017-06-21
A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy
Swedish Orphan Biovitrum
Phase 1/2 Completed
NCT00686725 2017-06-14
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00684567 2017-06-07
Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00094861 2017-03-14
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Swedish Orphan Biovitrum
Phase 2 Completed
NCT00813943 2017-01-30
CORE
EMD Serono
Phase 2 Completed
NCT00705198 2016-11-15
Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
Merck Sharp & Dohme LLC
Completed
NCT00527111 2016-11-03
Pre-op Rectal ChemoRad +/- Cetuximab
US Oncology Research
Phase 2 Completed